Targeted Disruption of Stat3 Reveals a Major Role for Follicular Stem Cells in Skin Tumor Initiation

Dae Joon Kim, Ken Kataoka, Dharanija Rao, Kaoru Kiguchi, George Cotsarelis, and John DiGiovanni

Department of Carcinogenesis, The University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas and Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Abstract
The initiation stage of mouse skin carcinogenesis involves the induction of mutations in keratinocyte stem cells (KSC), which confers a selective growth advantage allowing clonal expansion during tumor promotion. Targeted disruption of signal transducer and activator of transcription 3 (Stat3) in bulge region KSCs was achieved by treating K15.CrePR1 × Stat3B/− mice with RU486. Deletion of Stat3 prior to skin tumor initiation with 7,12-dimethylbenz(a)anthracene significantly increased the number of apoptotic KSCs and decreased the frequency of Ha-ras codon 61 A182→T transversion mutations in this cell population compared with wild-type littermates. Targeted disruption of Stat3 in bulge region KSCs at the time of initiation also dramatically reduced the number of skin tumors (by ~80%) produced following promotion with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. These results show that Stat3 is required for the survival of bulge region KSCs during tumor initiation. Furthermore, these data provide direct evidence that bulge region KSCs are the primary targets for the initiation of skin tumors in this model system. [Cancer Res 2009;69(19):OF1–8]

Introduction
The two-stage model of mouse skin carcinogenesis has been used for many years for studying mechanisms of chemical carcinogenesis (1). Skin tumors arise (papillomas followed by squamous cell carcinomas) after a single topical application of an initiator [e.g., 7,12-dimethylbenz(a)anthracene; DMBA] followed by repetitive applications of a tumor promoter (e.g., 12-O-tetradecanoylphorbol-13-acetate; TPA; ref. 2). During tumor initiation with DMBA, the ras gene (primarily Ha-ras) acquires mutations that confer a selective growth advantage to skin keratinocytes during tumor promotion (2). The end product of tumor promotion is the development of papillomas, a proportion of which undergoes malignant conversion (1, 2). Considerable effort has been expended on identifying the target cells for tumor development in this model of epithelial carcinogenesis.

In normal tissue, stem cells are responsible for growth and repair by regenerating and providing “new” progeny cells, thus balanced stem cell proliferation is important for tissue homeostasis (3, 4). Stem cells are the slowest cycling cells that share similar properties of quiescence, self-renewal, and immortality with cancer stem cells (5, 6). These characteristics of stem cells suggest that cancer might arise from slowly cycling embryonic-like cells, rather than differentiated cells (7). Keratinocyte stem cells (KSC) located in the bulge region of hair follicles are self-renewing cells that maintain hair growth and epidermal homeostasis by providing transit-amplifying cells that differentiate into cutaneous lineage cells (8–10). Studies focusing on KSCs as the origin of skin tumors have suggested that KSCs, especially those in the bulge region of hair follicles, could be potential targets for skin carcinogenesis (11–14).

Signal transducer and activator of transcription 3 (Stat3) is one of a family of cytoplasmic proteins that participate in normal cellular responses to cytokines and growth factors as a transcription factor (15–17). Upon activation by a wide variety of cell surface receptors, tyrosine phosphorylated Stat3 dimerizes and translocates to the nucleus and modulates the expression of target genes that are involved in various physiologic functions including apoptosis (e.g., survivin and Bcl-xl), cell cycle regulation (e.g., cyclin D1 and c-Myc), and tumor angiogenesis (e.g., vascular endothelial growth factor; refs. 17, 18). Studies have shown that constitutive activation of Stat3 is associated with a number of human tumors and cancer cell lines, including prostate, breast, lung, head and neck, brain, and pancreas, and its inhibition via various ways can suppress the growth of cancer cells by promoting apoptosis and inhibiting cell proliferation (15, 16, 19, 20), suggesting that Stat3 may play a critical role in cancer cell proliferation and survival. Recent studies have also revealed that Stat3 plays an important role in maintaining the pluripotency in embryonic stem cells including survival (21–23). Furthermore, recent statistical analyses on expression and transcription factor–binding data have provided evidence that Stat3 is one of the significant core regulators in mouse embryonic stem cells, in addition to key stem cell regulators including Oct4, Sox2, and Nanog (24).

Our laboratory has shown that Stat3 plays critical roles in both two-stage chemical-induced and UV-mediated skin carcinogenesis (25–31). In this regard, epidermal growth factor receptor–mediated activation of Stat3 occurs in mouse epidermis following topical treatment of diverse classes of tumor promoters, including TPA, okadaic acid, and chrysarobin (32). Furthermore, constitutive activation of Stat3 is observed in both papillomas and squamous cell carcinomas induced by two-stage and UVB-mediated carcinogenesis in mice (27, 28). Consistent with these observations, epidermis-specific Stat3-deficient mice were highly resistant to the development of skin tumors induced by both two-stage as well as UVB-induced skin carcinogenesis regimens (29, 31). Further studies have shown more directly that Stat3 is required for both the initiation and promotion stages of carcinogenesis (32). Further
evidence from these studies has suggested that Stat3 functions in maintaining the survival of DNA-damaged keratinocytes including bulge region KSCs and by mediating the cell proliferation necessary for the clonal expansion of initiated cells (reviewed in refs. 25, 26).

To further investigate the potential role(s) of Stat3 during skin carcinogenesis, and more specifically, its role in bulge region KSCs, we report for the first time the generation of mice in which Stat3 is specifically disrupted in bulge region KSCs using an inducible system (33, 34). Here, we show that Stat3 is absolutely required for the survival of bulge region KSCs during the initiation of skin tumors by DMBA. Furthermore, these data provide direct evidence that bulge region KSCs are the major targets for tumor initiation by DMBA in this model of epithelial multistage carcinogenesis.

Materials and Methods

Generation of K15.CrePR1 × Stat3<sup>fl/fl</sup> mice. The generation and characterization of K15.CrePR1 and Stat3<sup>fl/fl</sup> mice have both been previously described (33, 34). K15.CrePR1 mice, originally generated on a B6SJL/F1 genetic background, were crossed for at least 10 generations onto the FVB/N genetic background prior to breeding with Stat3<sup>fl/fl</sup> mice. K15.CrePR1 mice were bred with Stat3<sup>fl/fl</sup> mice to generate mice hemizygous for the K15.CrePR1 transgene and homozygous for Stat3 floxed alleles. Female K15.CrePR1 × Stat3<sup>wt/wt</sup> and K15.CrePR1 × Stat3<sup>fl/fl</sup> mice at 7 to 8 wk of age were used for the described experiments. The dorsal skin of each mouse was shaved 48 h before treatment. All experiments were carried out with strict adherence to institutional guidelines for minimizing distress in experimental animals.

Preparation of skin whole mounts and detection of enhanced green fluorescence protein. To prepare whole mounts, mice were sacrificed and the dorsalskin was shaved with electric clippers and treated topically with hair removal cream for 1 min prior to excision. The underlying fat and connective tissue were separated using scissors and the skin was cut into pieces (0.5 cm<sup>2</sup>). Whole skin pieces were placed on a glass slide and the localization of K15–enhanced green fluorescence protein (EGFP) was visualized using an inverted fluorescent microscope.

Analysis of epidermal apoptosis. Groups of mice (n = 3) were treated topically with 2 mg of RU486 or acetone for 5 consecutive days. One day after RU486 or acetone treatment, mice were treated with a single topical application of DMBA (100 nmol) or acetone (0.2 mL) on the dorsal skin and were sacrificed 24 h later. Skin sections were stained with an antibody to the active form of caspase-3 (R&D Systems, Inc.) and then treated with biotinylated anti-rabbit IgG and horseradish peroxidase–conjugated ABC reagent (BD PharMingen). Apoptotic keratinocytes were counted microscopically in at least three nonoverlapping fields in sections from each mouse.

Immunohistochemical analysis. Skin samples were fixed in either formalin or 70% ethanol, embedded in paraffin and sectioned (5 µm). After deparaffinization, the slides were microwaved for 15 min, washed with 0.1 mol/L of ammonium chloride (NH₄Cl)/PBS and incubated with 10% serum of host animal for secondary antibody/0.5% Triton X-100/1% bovine serum albumin in TBS for 40 min. Slides were then incubated for 2 h at room temperature with K15 (LHK15, diluted 1/50; Neomarkers) or caspase-3 (AF835, diluted 1/2,000; R&D Systems) antibodies diluted in 1% bovine serum albumin/PBS. After 2 h, slides were washed with 0.1 mol/L of NH₄Cl/PBS and incubated for 40 min with Alexa Fluor 488–conjugated goat anti-mouse IgG (A11029, diluted 1/2,000; Invitrogen) or Alexa Fluor...
594-conjugated goat anti-rabbit IgG (A11037, diluted 1/1,000; Invitrogen) secondary antibodies. After incubation, slides were washed with 0.1 mol/L of NH₄Cl/PBS and mounted using mounting medium with 4,6-diamidino-2-phenylindole (DAPI; Vectashield H-1200; Vector Laboratories, Inc.). The sections were analyzed using a confocal microscope (Zeiss 510 META).

Isolation of bulge region KSCs. Bulge region KSCs were isolated from control and K15.CrePR1 × Stat3fl/fl mice (n = 3–5) by fluorescence-activated cell sorting (FACS) analysis as previously described (35). After removal of fat and underlying subcutis, dorsal skins were incubated with dispase at 4°C overnight to separate epidermis from dermis. Dermis was digested with collagenase at 37°C for 1 h. Hair follicles were isolated by centrifugation at 300 × g for 5 min and at 52 × g for 5 min. Hair follicle cells were trypsinized at 37°C for 10 min, successively filtered (100 and 35 μm; BD Biosciences) and resuspended with DPBS/3% fetal bovine serum. Cells were labeled with an α6 integrin-PE (CD49f) antibody (BD PharMingen), a marker for basal keratinocytes (36), and a CD34-biotin antibody (ebiScience, Inc.), a hematopoietic stem cell marker that specifically labels hair follicle bulge region KSCs (37), followed by labeling with streptavidin coupled to APC. Cell sorting and isolation were performed on a BD FACS Aria SORP flow cytometer equipped with the BD FACSDiva 6.0 software (BD Biosciences). The purity of sorted populations was determined by post-sorting FACS analysis and generally exceeded 95%.

Mutation analysis. Groups of mice (n = 3) were treated topically with 2 mg of RU486 or acetone for 5 consecutive days. One day after the final RU486 or acetone treatment, mice were treated with a single topical application of DMBA (100 nmol) or acetone (0.2 mL) on the dorsal skin and sacrificed 1 or 10 d later. Genomic DNA was isolated and purified from bulge region KSCs (described above) using QIAGEN genomic-tip 20/G columns (Qiagen, Inc.). A mutation-specific PCR assay (38) was modified to detect Ha-ras codon 61 A182→T mutations in KSCs. Oligonucleotide primers specific for the normal and mutant Ha-ras gene were designed as follows: forward primer CD61-A, 5′-GGACTACTTAGACACAGCAGGTCA-3′ (normal Ha-ras gene); forward primer CD61-T, 5′-GGACTACTTAGACAGCAGGGTCA-3′ (mutant Ha-ras gene); and reverse primer CD61-REV, 5′-CATCGACCCAGGAGGCTCTCATGCC-3′. The mutant allele produces a 1.23 kb amplification product.

Two-stage skin carcinogenesis. At 8 wk of age, the dorsal skin of each mouse was shaved 48 h prior to treatment. K15.CrePR1 × Stat3fl/fl (group 1, n = 10) and K15.CrePR1 × Stat3wt/wt (group 2, n = 9) were treated topically with 2 mg of RU486 once daily for 5 consecutive days prior to initiation. Twenty-four hours after the last RU486 treatment, mice were initiated with a single application of 25 nmol of DMBA. Five weeks after initiation, both groups received twice-weekly applications of TPA at 6.8 nmol until the experiment was terminated. All compounds were topically applied in 0.2 mL acetone. The number and incidence of papillomas were determined weekly. Differences in tumor multiplicity and incidence were analyzed by the Mann-Whitney U test and the χ² test, respectively.

Preparation of protein lysates and Western blot analysis. Eight to 10 papillomas were pooled, placed into ice-cold radioimmunoprecipitation assay lysis buffer, incubated on ice for 10 min, snap-frozen in liquid nitrogen, rethawed, and centrifuged at 14,000 × g for 15 min at 4°C. The supernatant was separated by electrophoresis on 8% to 12% SDS/polyacrylamide gels. Separated proteins were electrophoretically transferred onto polyvinylidene difluoride membranes and blocked with 5% nonfat dry milk in PBS with 0.1% Tween 20 for 1 h at room temperature. Blots were incubated for 2 h at room temperature with primary antibodies specific for Stat3, phosphorylated Stat3 (Cell Signaling Technology, Inc.), and β-actin (Sigma-Aldrich). Blots were washed using PBS with 0.1% Tween 20 and subjected to corresponding horseradish peroxidase-conjugated secondary antibodies against rabbit or mouse (Amersham Biosciences), washed again using PBS with 0.1% Tween 20 and protein expression was detected with enhanced chemiluminescence Western blotting substrate (Pierce Biotechnology, Inc.).

Results

Localization and specificity of K15 expression. To further elucidate the functional roles of Stat3 in bulge region KSCs in skin carcinogenesis, inducible KSC-specific Stat3-deficient (K15.CrePR1 × Stat3fl/fl) mice were generated. To confirm the inducibility and specificity of K15 expression in these mice, we also generated K15.CrePR1 × Z/E mouse expressing GEFP in bulge region KSCs following inducible Cre activation. K15.CrePR1 × Z/E were then treated topically with the progesterone antagonist, RU486 (2 mg/mouse), once daily for 5 consecutive days. Following RU486 treatment, EGFP expression was observed in skin whole mounts. As shown in Fig. 1A and B, EGFP expression was observed in the highly restricted regions (i.e., bulge region) of hair follicles in K15.CrePR1 × Z/E mice (Fig. 1A). Further analysis

![Figure 2](https://example.com/figure2.png)
of skin whole mounts revealed that EGFP expression could be detected in the bulge region of ≥90% of the hair follicles in a given field (Fig. 1B). In Fig. 1C, we examined the expression of either K15 or Stat3 in K15.CrePR1 × Stat3<sup>wt/wt</sup> and K15.CrePR1 × Stat3<sup>fl/fl</sup> mice after RU486 treatment. As shown in representative skin sections after staining, bulge region KSCs stained intensely for K15 in both genetic backgrounds as expected. In contrast, nuclear staining for Stat3 was observed in K15.CrePR1 × Stat3<sup>wt/wt</sup> mice whereas in K15.CrePR1 × Stat3<sup>fl/fl</sup> mice it was greatly reduced or absent. These data confirmed that the treatment protocol and specificity of K15-driven expression of Cre in bulge region KSCs was sufficient for subsequent experiments.

KSC-specific disruption of Stat3 inhibits skin tumor initiation. To investigate the effect of Stat3 deficiency in bulge region KSCs on skin tumor initiation and skin carcinogenesis, K15.CrePR1 × Stat3<sup>fl/fl</sup> and control mice were subjected to a two-stage chemical carcinogenesis regimen. K15.CrePR1 × Stat3<sup>fl/fl</sup> mice were treated with RU486 (2 mg/mouse) once daily for 5 days prior to initiation (group 2). Control mice containing wild-type Stat3 alleles also received RU486 prior to initiation (group 1). Tumor promotion with TPA was begun 5 weeks after initiation in both groups. K15.CrePR1 × Stat3<sup>fl/fl</sup> mice treated with RU486 before initiation showed a significant reduction in tumor development compared with the control group. In this regard, only 30% of K15.CrePR1 × Stat3<sup>fl/fl</sup> mice developed papillomas after 22 weeks of promotion with TPA, whereas 100% of control mice developed papillomas (Fig. 2A). More importantly, there was an ~80% reduction in the average number of papillomas per mouse in K15.CrePR1 × Stat3<sup>fl/fl</sup> mice at the end of the experiment (Fig. 2B). These data indicate that deleting Stat3 specifically in bulge region KSCs dramatically inhibits tumor initiation by DMBA. Furthermore, the data indicate that a majority of skin tumors arise from bulge region KSCs.

Western blot analysis of protein lysates from papillomas that arose in K15.CrePR1 × Stat3<sup>fl/fl</sup> mice showed that both the levels of Stat3 and phosphorylated Stat3 were similar to that seen in papillomas from the control mice (Fig. 2C). These data indicate that Stat3 is required for the development of skin tumors in this model system. Furthermore, the presence of Stat3 in skin tumors from K15.CrePR1 × Stat3<sup>fl/fl</sup> mice suggests that either Stat3 deletion in bulge region KSCs is not complete and/or that some skin tumors arise from another stem cell compartment, as has been suggested by others (5, 39, 40). Figure 3 shows that within the population of hair follicle cells that express K15, only a portion seem to have a significant deletion of Stat3, as assessed by immunofluorescence staining. These data suggest that the overall efficiency of Stat3 deletion is <100% and may explain why some tumors arose in K15.CrePR1 × Stat3<sup>fl/fl</sup> mice.

Stat3 deletion in bulge region KSCs increases DMBA-induced apoptosis. During tumor initiation, carcinogen-induced DNA damage may be repaired or damaged cells may undergo apoptosis. Both of these processes represent protective mechanisms against the development of tumors, through elimination of cells that might otherwise have the potential to acquire mutations. Cells that escape from these protective mechanisms are at risk for acquiring mutations that may confer a growth advantage and allow clonal expansion during the tumor promotion stage (reviewed in...
Role of Stat3 in Follicular Stem Cells

Ref. 1, 41). To examine the effect of Stat3 deficiency in bulge region KSCs on DMBA-induced apoptosis, K15.CrePR1 × Stat3[^B/a] mice were treated topically once daily with RU486 (2 mg/mouse) for 5 days and 24 h later received DMBA treatment. Twenty-four hours after treatment with DMBA, the number of apoptotic keratinocytes was determined by active caspase-3 staining in skin sections compared with similarly treated control mice. As shown in Fig. 4, there was no difference in the number of apoptotic keratinocytes in the interfollicular epidermis in K15.CrePR1 × Stat3[^B/a] mice compared with control mice following DMBA treatment. In contrast, topical application of DMBA to K15.CrePR1 × Stat3[^B/a] mice resulted in a significant increase in the number of bulge region KSCs undergoing apoptosis compared with control (K15.CrePR1 × Stat3[^WT]) mice (Fig. 4B). The selectivity for apoptosis in bulge region KSCs of K15.CrePR1 × Stat3[^B/a] mice treated with DMBA can be seen in Fig. 4C. In addition, Fig. 4D provides confocal images demonstrating that cells undergoing apoptosis (detected by active caspase 3 staining; red) in hair follicles are the cells that express K15 (green).

Stat3 deletion in bulge region KSCs reduces α6^+CD34^+ cells and cells with Ha-ras mutations. DMBA, a widely studied polycyclic aromatic hydrocarbon requires metabolic activation to highly reactive diol-epoxides for its action as a skin tumor initiator and chemical carcinogen (reviewed in ref. 1). These diol-epoxides bind covalently to DNA bases, especially deoxyadenosine, and form specific DNA adducts that lead to mutations. More than 90% of the papillomas initiated by DMBA in the mouse skin model contain an activated Ha-ras gene with a single A to T transversion mutation at the second position of codon 61 (i.e., Ha-ras codon 61 A[^182]→T mutation; refs. 1, 41, 42). The increased apoptosis in bulge region KSCs of K15.CrePR1 × Stat3[^B/a] mice as shown in Fig. 4 suggested that Stat3 deletion in bulge region KSCs would lead to a reduction in frequency in Ha-ras mutations if these cells represented the target cell population. To investigate this further, we determined the number of bulge region KSCs isolated from hair follicles using FACS analysis. In addition, we examined the frequency of Ha-ras codon 61 (A[^182]→T) mutations in this population of cells. Bulge region KSCs express high levels of α6-integrin, a proliferation-associated cell surface marker for basal keratinocytes (40, 43). In addition, these cells express the hematopoietic stem cell marker CD34, a specific cell surface marker for bulge region KSCs (37).

As shown in Fig. 5, there was a reduction in the percentage of α6^+CD34^+ (including both α6^[low] and α6^[high] populations) in K15.CrePR1 × Stat3[^B/a] mice 24 hours after treatment with either 100 or 1,000 nmol of DMBA (Fig. 5A, B, and C, respectively). Notably, Ha-ras codon 61 A[^182]→T mutations were detected in α6^+CD34^+ hair follicle cells 1 day after treatment of control mice with DMBA (Fig. 5D). In contrast, the Ha-ras codon 61 mutant band was significantly reduced at this time point in K15.CrePR1 × Stat3[^B/a] mice. Similar observations were obtained when cells were isolated at 10 days after treatment with DMBA (Fig. 5D). Collectively, these data show that Stat3 deletion in bulge region KSCs leads to a loss of α6^+CD34^+ keratinocytes and a decrease in the number of these

Figure 4. Response of K15.CrePR1 × Stat3[^B/a] mice to DMBA-induced apoptosis. Groups of K15.CrePR1 × Stat3[^W/T] and K15.CrePR1 × Stat3[^WT] mice (n = 3/group) were treated with RU486 (2 mg in 0.2 mL acetone) topically for 5 consecutive days. Twenty-four hours after the last treatment of RU486, mice received a single topical application of DMBA (100 nmol) and were sacrificed 24 h later. Skin sections were harvested and apoptotic cells were quantified by immunostaining for caspase-3. A. Quantitation of caspase-3–positive cells per centimeter of interfollicular epidermis. B. Quantitation of caspase-3–positive cells per centimeter of follicular epidermis in K15.CrePR1 × Stat3[^W/T] and K15.CrePR1 × Stat3[^WT] mice after DMBA treatment (*, P < 0.05 by Mann–Whitney U test). C. Representative caspase-3 stain of epidermis from K15.CrePR1 × Stat3[^W/T] mice following 3 days of treatment with DMBA. Note that caspase-3–positive cells were found in the bulge region of hair follicles (arrow) and the follicular epidermis (arrowhead); bar, 20 μm. D. Colocalization of K15 and active caspase-3 in bulge region KSCs of K15.CrePR1 × Stat3[^WT]. Skin sections were stained with antibodies against K15 (green) and caspase-3 (red). DAPI (blue) was used for nuclear staining.

www.aacrjournals.org OF5 Cancer Res 2009; 69: (19). October 1, 2009

Published OnlineFirst September 8, 2009; DOI: 10.1158/0008-5472.CAN-09-1180

Downloaded from cancerres.aacrjournals.org on April 18, 2017. © 2009 American Association for Cancer Research.
cells with signature Ha-ras mutations induced by DMBA. These data provide a mechanistic explanation for the dramatic reduction in tumor initiation seen in K15.CrePR1 × Stat3<sup>fl/fl</sup> mice (again see Fig. 2).

**Discussion**

As noted in the Introduction, recent studies from our laboratory using skin-specific gain and loss of function Stat3 transgenic mice have provided evidence that Stat3 has critical roles in both chemically and UVB-induced skin carcinogenesis (29–31). Based on these studies, we hypothesized that Stat3 was required for the survival of DNA-damaged keratinocytes, especially bulge region KSCs during the initiation of skin tumors. In the current study, we provide direct evidence that Stat3 is required for the survival of DNA-damaged KSCs located in the bulge region of hair follicles. In the absence of Stat3, bulge region KSCs are prone to undergo apoptosis following treatment with DMBA. This leads to a decrease in bulge region KSCs that have Ha-ras mutations and ultimately a dramatic inhibition of skin tumor initiation as assessed in a two-stage skin tumorigenesis assay. Finally, the current data provide strong evidence that bulge region KSCs are the primary targets for tumor initiation by DMBA in this model of epithelial multistage carcinogenesis.

As shown in Fig. 4, DMBA-induced apoptosis was significantly increased in the epidermis of K15.CrePR1 × Stat3<sup>fl/fl</sup> mice after inducible deletion of Stat3 in bulge region KSCs. Close examination of skin sections stained for active caspase-3 revealed that the increase in apoptotic cells of K15.CrePR1 × Stat3<sup>fl/fl</sup> mice treated with RU486 was localized to the bulge region of the hair follicles. This was further confirmed by showing that the number of α<sup>6</sup>CD34<sup>+</sup> cells (i.e., including both α<sup>6</sup><sub>low</sub> and α<sup>6</sup><sub>high</sub> populations) was reduced following DMBA treatment and through colocalization of K15 staining with active caspase-3 staining. Stat3 is known to regulate a number of antiapoptotic genes, such as Bcl-x<sub>L</sub>, Mcl-1, and survivin, leading to enhanced cell survival (44, 45). Our previous studies have suggested that one or more of these Stat3-regulated genes may be responsible for protecting DNA-damaged bulge region KSCs. In this regard, recent studies using skin-specific Bcl-x<sub>L</sub>-deficient mice have shown a partial role of Bcl-x<sub>L</sub> in the protection of bulge region KSCs against DMBA-induced apoptosis in vivo (46). In addition, Stat3-mediated regulation of survivin expression and subsequent regulation of Oct-4, a POU homeobox transcription factor, has been shown to protect embryonic stem cells from stress-related apoptosis (47). Furthermore, elevated expression of survivin in bulge region KSCs may confer protection from anoikis (48).

Evidence has accumulated that KSCs are the targets for chemical carcinogenesis in mouse skin (reviewed in ref. 11). Cells with properties of KSCs are found at the base of epidermal proliferative units in the interfollicular epidermis and in the bulge region of the hair follicles (8). These properties include slow-cycling, label-retaining properties (e.g., with <sup>3</sup>H<sub>Idr</sub> or bromodeoxyuridine; the latter referred to as label-retaining cells or LRC), and high proliferative capacity (9, 49). Furthermore, bulge region KSCs were found to express the hematopoietic stem cell marker, CD34 (37).
Characterization of o6'-CD34+ cells from the bulge region confirmed that these cells were slow cycling, colocalized with LRCs, and exhibited high proliferative capacity in culture (35, 37). Morris and colleagues also showed that LRCs, not pulse-labeled cells, could undergo mitosis and remain on the basal layer (13), implying that LRCs have an ability for clonal expansion during skin tumor promotion. In addition, Morris and colleagues showed that LRCs could retain carcinogen-DNA adducts (9). Trempus and colleagues also reported that CD34 expression in KSCs is required for TPA-induced hair follicle stem cell activation and tumor formation via the two-stage carcinogenesis protocol (12). In addition to the bulge region KSC stem cell niche, Nijhoff and colleagues (50) recently identified a novel murine progenitor cell population localized to a previously uncharacterized region above the bulge region. Cells in this region react with antibodies to the thyophilic epithelial progenitor marker MTS24. MTS24-positive cells do not express CD34 or K15 but possess a high proliferative capacity similar to bulge region KSCs and may be derived from the latter (50). Furthermore, other stem/progenitor cells that do not express MTS24 or K15/CD34 may also reside in the same general region called the upper isthmus (51). The question of which stem/progenitor cells are the primary target population has remained controversial. However, recent data (11) has suggested that both bulge region KSCs as well as KSCs found in the interfollicular epidermis may contribute to skin tumor development. Our current data shows that bulge region KSCs are the primary targets for the initiation of skin tumors by DMBA in mouse skin.

Another interesting aspect of our current study was the observation that A1462T transversion mutations in the Ha-ras gene could be detected in bulge region KSCs (i.e., o6'-CD34+ cells) as early as 1 day following DMBA treatment (Fig. 5). Furthermore, analysis of o6'-CD34+ cells isolated from K15.CrePR1 × Stat3-/- mice treated with RU486 followed by DMBA showed a significant reduction in the frequency of Ha-ras mutation at both 1 and 10 days after treatment with DMBA. Mutations in Ha-ras are believed to represent a tumor-initiating event for mouse skin carcinogenesis in this model system (reviewed in refs. 1, 52, 53). Our current study shows for the first time that distinct, carcinogen-specific mutations can be detected in the Ha-ras gene of bulge region KSCs. Furthermore, in the absence of Stat3, there was a decrease in the frequency of Ha-ras mutations in bulge region KSCs due to loss of cells following DMBA-induced DNA damage. Overall, these data provide further support for the conclusion that bulge region KSCs are the primary targets for initiation of mouse skin tumors by DMBA.

In conclusion, through inducible deletion of Stat3 in bulge region KSCs, we provide strong evidence for its role in the initiation of skin tumors by the carcinogen DMBA. Furthermore, the mechanism involves control of survival of bulge region KSCs following DNA damage by reactive metabolites of DMBA that lead to mutations in Ha-ras. The current data also provides strong evidence that bulge region KSCs are the primary targets for tumor initiation in this model system. Overall, these studies suggest that targeting Stat3 in KSCs is a viable strategy for the prevention of skin cancer.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
Received 3/31/09; revised 7/8/09; accepted 7/29/09; published OnlineFirst 9/8/09.
Grant support: National Cancer Institute grant CA76520 (J. DiGiovanni), University of Texas M.D. Anderson Cancer Center Support grant CA16672, and National Institute of Environmental Health Sciences Center grant ES07784. Funding as an Odyssey Fellow was supported by the Odyssey Program and the H-E-B Award for Scientific Achievement at The University of Texas M.D. Anderson Cancer Center (D.J. Kim).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References
8. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. The cost of publication of this article was defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Targeted Disruption of Stat3 Reveals a Major Role for Follicular Stem Cells in Skin Tumor Initiation

Dae Joon Kim, Ken Kataoka, Dharanija Rao, et al.

Cancer Res  Published OnlineFirst September 8, 2009.

Updated version  Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-09-1180

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.